Anti-reflux mucosectomy (ARMS) for refractory gastroesophageal reflux disease

Table 1 Study and population characteristics

Author, year	Technique	No. patients	Age, mean years (SD)	Mean follow-up time	Clinical success		Partial clinical success	Complete clinical success	24 h esophageal pH monitoring
									DeMeester score mean (SD)		Mean esophageal acid exposure time (%) (Ph＜4) (SD)
									Preoperation	Postoperation	Preoperation			Postoperation
Inoue et al. [12], 2014	ARMS	10	NR	2 months	10		0	10	NR		29.1			3.1
Ota et al. [22], 2014	ARMS	13	NR	6 months	12	0		12	NR		10.4 (±15.5)			7.4 (±10.6)
Bapaye et al. [25], 2017	ARMS	15	40.8 (19.2)	1 months	15		4	11	85.8	5.9	NR
Benias et al. [15], 2018	RAP	10	56.5	5–27 months	10		0	10	NR		NR
Hu et al. [16], 2018	PECC	16	53	3, 6 months	16		0	16	125.5 (±89.64)	20.32 (±15.22)	35.55 (±26.2)			4.72% (±3.78%)
Patil et al. [17], 2019	ARMS-C (cap-EMR)	62	36 (9.9)	2, 6, 12 months	55		12	43	76.8 (18.3)	14.3 (6.1)	NR
Hedberg et al. [19], 2019	ARM-b	19	57.1	3 week, 6 months	13		0	13	NR		NR
Prasad et al. [32], 2019	ARMS	11	41–60	6 months	8		0	8	NR		NR
Yoo et al. [18], 2020	ARMS-C	33	51.3 (16.3)	6 months	31		10	21	14.3 (10.9)	7.7 (9,4)	3.1(3.1)		1.8 (2.4)
Monino et al. [27], 2020	ARM-b	21	56.78 (14.47)	5, 10 months	16		4	12	NR		NR
Inoue et al. [21], 2020	ARMA	12	54.4	2 months	12	0		12	33.5	2.8	9	0.5
Hernandez et al. [24], 2020	ARAT(ARMA)	108	36.5	3,6,12,24,36 months	96	0		96	42.5	9.1	18.8	2.8
Debourdeau et al. [20], 2020	ARMS-b	6	44(7.5)	3 months	3	2		1	NR		NR
Wong et al. [28], 2020	ARMS-b	33	55 (17)	6 months, 1 year, 2 years	30	0		30	NR		NR
Sumi et al. [23], 2021	ARMS	109	54 (15.7)	2–6 months, 1 year	42		0	42	64.4 (75.7)	24.9 (36)	20.8 (24.3)	6.9 (10.4)

Author, year	GERD-HRQL score		GERD-Q score mean (SD)		Adverse events			The use of acid inhibitors	Hill grade
	GERD-HRQL score		GERD-Q score mean (SD)		Dysphagia	Bleeding	Others		Hill grade
	Preoperation	Preoperation	Preoperation	Preoperation	Dysphagia	Bleeding	Others		Post-operation
Inoue et al. [12], 2014	NR		NR		2	NR	NR	All discontinued	Grade I
Ota et al. [22], 2014	NR		NR		1	NR	NR	3 discontinued 3 reduced in dose 6 at the usual dose	NR
Bapaye et al. [25], 2017	40.4	7.6	NR		1	0	2	NR	NR
Benias et al. [15], 2018	26.6 (±3.9)	4.3 (±2.4)	NR		1	NR	NR	6 discontinued 4 reduced in dose	Grade I
Hu et al. [16], 2018	36.5	10	NR		3	0	1	NR	NR
Patil et al. [17], 2019	NR		10.6 (1.9)	3.4 (1.5)	5	0	4	43 discontinued 12 reduced in dose 7 at the usual dose	NR
Hedberg et al. [19], 2019	Improved		NR		3	1	1	13 discontinued	NR
Prasad et al. [32], 2019	NR		NR		0	0	0	NR	NR
Yoo et al. [18], 2020	NR		11.1 (3.1)	6.8 (3.1)	2	0	0	21 discontinued 10 reduced in dose	Grade I
Monino et al. [27], 2020	25.6 (8.8)	16.8 (6.4)	12.5 (1.5)	9 (2)	3	1	0	3 months 76% Decrease/discontinue 6 months 72% Decreased/discontinued	19 improved
Inoue et al. [21], 2020	30.5	12	NR		1	0	0	5 discontinued	Grade I (1.9–0.5)
Hernandez et al. [24], 2020	36.5	10	NR		14	0	0	78.6% 3 years discontinued	Grade I
Debourdeau et al. [20], 2020	30.6 (7.7)	6.8 (3.7)	13.3 (1.1)	6.2 (4.0)	1	1	0	1 discontinued 2 reduced in dose 3 at the usual dose	NR
Wong et al. [28], 2020	16 (12)	6 (7.1)	NR		3	1	1	90.9% discontinued	Grade I
Sumi et al. [23], 2021	NR		NR		14	2	1	50% 1 year discontinued	NR

GERD-HRQL, GERD-Health Related Quality of Life, GERD-Q GERD-questionnaire, mon month, SD standard deviation, RAP resection and plication, PECC Peroral endoscopic cardinal constriction, ARMS-C anti-reflux mucosectomy using cap-assisted endoscopic mucosal resection (EMR-C), ARAT antireflux ablation therapy, ARMA anti-reflux mucosal ablation, ARMS-b antireflux mucosectomy band, NR not reported

ISSN: 2047-783X